PL3837256T3 - Związki i kompozycje mocznika jako inhibitory smarca2/brm-atpazy - Google Patents

Związki i kompozycje mocznika jako inhibitory smarca2/brm-atpazy

Info

Publication number
PL3837256T3
PL3837256T3 PL19779145.2T PL19779145T PL3837256T3 PL 3837256 T3 PL3837256 T3 PL 3837256T3 PL 19779145 T PL19779145 T PL 19779145T PL 3837256 T3 PL3837256 T3 PL 3837256T3
Authority
PL
Poland
Prior art keywords
smarca2
brm
compositions
urea compounds
atpase inhibitors
Prior art date
Application number
PL19779145.2T
Other languages
English (en)
Inventor
Christopher Adair
Julien Papillon
Katsumasa Nakajima
Troy Douglas SMITH
Rukundo Ntaganda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3837256T3 publication Critical patent/PL3837256T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL19779145.2T 2018-08-17 2019-08-12 Związki i kompozycje mocznika jako inhibitory smarca2/brm-atpazy PL3837256T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17
PCT/IB2019/056847 WO2020035779A1 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as smarca2/brm atpase inhibitors

Publications (1)

Publication Number Publication Date
PL3837256T3 true PL3837256T3 (pl) 2023-07-10

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19779145.2T PL3837256T3 (pl) 2018-08-17 2019-08-12 Związki i kompozycje mocznika jako inhibitory smarca2/brm-atpazy

Country Status (21)

Country Link
US (2) US11958846B2 (pl)
EP (2) EP4219488A1 (pl)
JP (1) JP7328323B2 (pl)
KR (1) KR20210047313A (pl)
CN (2) CN118666832A (pl)
AU (1) AU2019322325B2 (pl)
BR (1) BR112021002632A2 (pl)
CA (1) CA3107097A1 (pl)
CY (1) CY1126039T1 (pl)
DK (1) DK3837256T3 (pl)
ES (1) ES2946060T3 (pl)
FI (1) FI3837256T3 (pl)
HR (1) HRP20230477T1 (pl)
HU (1) HUE061963T2 (pl)
LT (1) LT3837256T (pl)
MX (1) MX2021001804A (pl)
PL (1) PL3837256T3 (pl)
PT (1) PT3837256T (pl)
RS (1) RS64238B1 (pl)
SI (1) SI3837256T1 (pl)
WO (1) WO2020035779A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
CN112153984A (zh) 2018-01-30 2020-12-29 福宏治疗公司 化合物及其用途
EP4219488A1 (en) * 2018-08-17 2023-08-02 Novartis AG Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
WO2025007147A2 (en) * 2023-06-30 2025-01-02 Dana-Farber Cancer Institute, Inc. Methods for sensitizing drug-resistant cancer cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US2871243A (en) * 1956-10-26 1959-01-27 May & Baker Ltd 5-amino-3-methyl-isothiazole and process
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
HUP0400021A3 (en) 2001-05-24 2008-03-28 Leo Pharma As Novel pyridyl cyanoguanidine derivatives and pharmaceutical compositions containing them
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1611128A2 (en) 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosteric modulators of the nicotinic acetylcholine receptor
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
JP2011513203A (ja) 2008-03-14 2011-04-28 大塚製薬株式会社 Ｍｍｐ−２及び／又はｍｍｐ−９阻害剤
CN103880737A (zh) * 2014-02-27 2014-06-25 浙江泰达作物科技有限公司 1-(2-氯-4-吡啶基)-3-苯基脲的制备方法
ES2747249T3 (es) 2014-07-17 2020-03-10 Sunshine Lake Pharma Co Ltd Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN105481723B (zh) 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2018187414A1 (en) 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions
EP4219488A1 (en) 2018-08-17 2023-08-02 Novartis AG Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Also Published As

Publication number Publication date
ES2946060T3 (es) 2023-07-12
FI3837256T3 (fi) 2023-05-15
AU2019322325A1 (en) 2021-02-18
EP3837256B1 (en) 2023-03-08
US20240270738A1 (en) 2024-08-15
DK3837256T3 (da) 2023-05-30
US11958846B2 (en) 2024-04-16
WO2020035779A1 (en) 2020-02-20
EP4219488A1 (en) 2023-08-02
BR112021002632A2 (pt) 2021-05-11
LT3837256T (lt) 2023-06-12
MX2021001804A (es) 2021-04-19
AU2019322325B2 (en) 2022-01-20
JP7328323B2 (ja) 2023-08-16
CY1126039T1 (el) 2023-11-15
JP2021534147A (ja) 2021-12-09
US12358906B2 (en) 2025-07-15
PT3837256T (pt) 2023-05-23
CN112585136A (zh) 2021-03-30
CN112585136B (zh) 2024-06-25
US20210323956A1 (en) 2021-10-21
RS64238B1 (sr) 2023-06-30
HRP20230477T1 (hr) 2023-07-21
HUE061963T2 (hu) 2023-09-28
CA3107097A1 (en) 2020-02-20
EP3837256A1 (en) 2021-06-23
KR20210047313A (ko) 2021-04-29
SI3837256T1 (sl) 2023-07-31
CN118666832A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
PL3837256T3 (pl) Związki i kompozycje mocznika jako inhibitory smarca2/brm-atpazy
IL277079A (en) Cartirin preparations and methods of use
IL276082B1 (en) DNA-pk inhibitor compounds, preparations containing them and their uses
IL276080A (en) DNA-pk suppressor compounds, UTP-containing preparations and their uses
SG11202104687SA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL285302A (en) Compounds, preparations and methods
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL289754A (en) Piperidinylmethylpurinamines as nsd2 inhibitors and anticancer agents
IL263082B (en) New compounds as ototaxin inhibitors and pharmaceutical preparations containing them
IL254383A0 (en) Alpha-cinnamide compounds and preparations as hdac8 inhibitors
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
EP3697791A4 (en) HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
IL285595A (en) Spt5 inhibitors and uses thereof
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
ZA201704116B (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
ZA202001320B (en) Compounds and compositions for ire1 inhibition
IL278701A (en) Heterofused pyridones and their use as IDH inhibitors
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
PT3724196T (pt) Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
IL287120A (en) Compounds, preparations and methods
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
EP3596082A4 (en) CDPK1 INHIBITORS, ASSOCIATED COMPOSITIONS AND PROCESSES
PL3568203T3 (pl) Związki i kompozycje
GB201614961D0 (en) Compounds and compositions for use